Romidepsin (FK228, Depsipeptide)

製品コードS3020 別名:FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide)化学構造

分子量(MW):540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 26062.00
JPY 79182.00
JPY 115702.00

カスタマーフィードバック(6)

  • Concentration over time for each dose cohort of romidepsin (B).

    Blood, 2018, 131(4):397-407. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PBMCs from a patient were incubated with diverse agents (2 μM Compound E, 2 nM Bortezomib and 1nM Romidepsin) for 48 hours. Apoptosis detection was performed by Annexin V/PI staining and analyzed by flow cytometry. Annexin V+/PI− (lower right quadrant) areas stand for early apoptotic cells, and Annexin V+/PI+ (upper right quadrant) areas stand for late apoptotic or necrotic cells.

    Leukemia, 2015, 29(3):556-66. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
特性 More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
ターゲット
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外試験

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 M2LYPGNmdGxiVnnhZoltcXS7IFHzd4F6 NXPPcHhVOi53LUG1JI5O NGjyZmk4OiCq NITCVXdqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NET3eFYzPTd7MEmwOy=>
U2932  MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIrN[I4zNjVvMUWgcm0> MXW3NkBp NYjt[no{cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= Mo\XNlU4QTB7MEe=
OCI-LY7 MlOwR4VtdCCYaXHibYxqfHliQYPzZZk> MUGyMlUuOTVibl2= NWXNbnhtPzJiaB?= NWrnWmxWcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= M3L5flI2PzlyOUC3
Farage M{\4fGNmdGxiVnnhZoltcXS7IFHzd4F6 MoDGNk42NTF3IH7N M{HOOFczKGh? M2\tZ4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NWHyZXFnOjV5OUC5NFc>
LY7/EBV NWLHNIdWS2WubDDWbYFjcWyrdImgRZN{[Xl? MmDGNk42NTF3IH7N NHLVfVU4OiCq MWDpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MX6yOVc6ODlyNx?=
U2932/EBV MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4HmelIvPS1zNTDuUS=> NI\wPYc4OiCq M3iw[4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MlHtNlU4QTB7MEe=
HCT116 M2\SRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnQeodsPS13MECwJI5O MVuyOEBp MUXEUXNQ MVnpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= Mn6yNlU1QTJ3MUW=
ACH-2 NFvs[I9HfW6ldHnvckBCe3OjeR?= M3X3UVEuQSCwTR?= MWCyOEBp M1nuT4lv\HWlZYOgTGlXNTFiRX72JIV5eHKnc4Ppc44> MXSyOVE1QTR4Nx?=
MCF-10A MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f0eWlEPTB;MD6xO:KyOC5yMTDuUS=> MojjNlQ6PTR6NU[=
MCF-7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG4UlBKSzVyPUGuNVDDuTBwMkCgcm0> M2DGSlI1QTV2OEW2
SK-BR-3 Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO3VWcyUUN3ME2xMlAxyrFyLkO1JI5O MnP1NlQ6PTR6NU[=
MDA-MB-231 NXPIUHFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXHPFd6UUN3ME2wMlY5yrFyLkG0JI5O M{DkXVI1QTV2OEW2
PC3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPLTWM2OD1zLk[1xtExNjN3IH7N NInRU2IzPDl3NEi1Oi=>
HCT116 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi5T5lKSzVyPUGuNFDDuTBwMECgcm0> MoP5NlQ6PTR6NU[=
HCT116-p21-/- M4DWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr6OVlRUUN3ME2xMlI3yrFyLkO3JI5O M2T0dVI1QTV2OEW2
S1 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonLTWM2OD15Lk[3xtExNjJ7IH7N Mnm0NlQ6PTR6NU[=
SW620 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO3TWM2OD1yLkmzxtExNjJ7IH7N MkfHNlQ6PTR6NU[=
LOX-IMVI NWfUXGV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\mZXlKSzVyPUCuPFfDuTBwMEOgcm0> MVmyOFk2PDh3Nh?=
UACC-62 NWKxeGJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG0TWM2OD1yLkW2xtExNjF4IH7N Mkn5NlQ6PTR6NU[=
MDA-MB-435 NGHjeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K1W2lEPTB;MD65NOKyOC5yNjDuUS=> NXjzbFJMOjR7NUS4OVY>
SF-295 M4L6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG3b2JKUUN3ME2wMlg5yrFyLkG1JI5O MXeyOFk2PDh3Nh?=
A549 M2DqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17uXWlEPTB;MT6yOuKyOC5{NDDuUS=> Mn\GNlQ6PTR6NU[=
H460 NYrsfndIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJwNUlCtVAvQDBibl2= MW[yOFk2PDh3Nh?=
EKVX NIDPXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T1[WlEPTB;MT6zN:KyOC5|NDDuUS=> MofLNlQ6PTR6NU[=
H146 NIjxOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMkNCtVAvODdibl2= MmDJNlQ6PTR6NU[=
H526 NVnzS4ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PwcGlEPTB;MD6xOeKyOC5yMzDuUS=> MofhNlQ6PTR6NU[=
HuT-78 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwN{RCtVAvPDRibl2= MmHqNlQ6PTR6NU[=
HA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULlOFZNOC54MkWtNVBvVQ>? M4LjUFQ5KGh? M1XzNIlv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj M4CwSVI1PzdzNUGw
MS-275 NFnVXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTod4xsOC54MkWtNVBvVQ>? M3KwT|Q5KGh? Ml;rbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> MWiyOFc4OTVzMB?=
CD4 T Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYe0PEBp MkD1SWM2OD12LkZCtVEvOCCwTR?= Mo\6NlQ4OjJ2NUS=
CD4 T Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPjZZg1QCCq MWnDR|UxRTFyN9MxNVI3KG6P NVPvOItJOjR5MkK0OVQ>
CD4+ T M3HpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfsSHZFTUN3ME2zJI5O MXWyOFQ6PTFyNR?=
A549 M1fVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf3NVDjiJNzMEFCpI5O M1ns[lI1NzN4L{S4JIg> NVrROmo{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M4i5ZlI1PDh3N{m5
JJN3 M3vjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDWZ3ozPC92ODDo NUTnSYdwTUN3MEyx5qCKdk19IES45qCKcA>? NGnIU2kzPDB|MEG1NC=>
OPM-2 NYXHbVgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSxRpE6OjRxNEigbC=> NWDpOZR{TUN3MIO9NgKBkW6POzC0PQKBkWh? NWntOoVFOjRyM{CxOVA>
RPMI-8226 NEDaTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf4Z|AzPC92ODDo M13iZ2VEPTC|PUGuPQKBkW6POzC0PQKBkWh? M1THWVI1ODNyMUWw
U266 NGfufVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYThOndYOjRxNEigbC=> NGLQPFFGSzVyc{2xNQKBkW6POzC0PQKBkWh? NUDUO3duOjRyM{CxOVA>
CA46 M1zDWWFxd3C2b4Ppd{BCe3OjeR?= NYHDd4NzPiCq MkLWbY5lfWOnczDicJVvfCCjcH;weI9{cXN? M{D3b|I{QTZ4MU[0
DG75 MYHBdI9xfG:|aYOgRZN{[Xl? Mn;rOkBp M4fkcYlv\HWlZYOgco8h[XCxcITvd4l{ NYfJVmJLOjN7Nk[xOlQ>
Ramos M3PVNmFxd3C2b4Ppd{BCe3OjeR?= M1LJSFYhcA>? MnTpbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz MUKyN|k3PjF4NB?=
ST486 M4PxOmFxd3C2b4Ppd{BCe3OjeR?= NVntWlNFPiCq NXu2V2RGcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ NHH4OY0zOzl4NkG2OC=>
HuT78 MV\BdI9xfG:|aYOgRZN{[Xl? M{m1b|EwOTBxMUCwJI5O NH\nSnY1QCCq NX7vW2FQcW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=> MV6yN|U{Ojd|Mh?=
DpVp35 M13ycmFxd3C2b4Ppd{BCe3OjeR?= MVSxM|ExNzFyMDDuUS=> NHfO[ZU1QCCq MYfpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? Ml20NlM2OzJ5M{K=
DpVp50 NUDDOJVWSXCxcITvd4l{KEG|c3H5 MWexM|ExNzFyMDDuUS=> MX:0PEBp NIroZWNqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NFPVO2EzOzV|MkezNi=>
DpP75  NGLPUlBCeG:ydH;zbZMhSXO|YYm= NV7pblVLOS9zMD:xNFAhdk1? MYK0PEBp NEHYbZZqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NVTUZW1mOjN3M{K3N|I>
SKOV-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrqNgKBmzJybl2= NVXteWNmPzJiaB?= M4j1XWROW09? NVzZTmRHemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MljHNlMxOTB|NEi=
Brca1 WT Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGx5qCUOjCwTR?= MXy3NkBp Mn3CSG1UVw>? NV\WelJXemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MUKyN|AyODN2OB?=
Brca1 Null Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjLNgKBmzJybl2= M3y4WVczKGh? NVmxNlZXTE2VTx?= MWHy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MmrXNlMxOTB|NEi=
OVCAR-8  NWfucINRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV21bVE6OeLCk{Kwcm0> M{[3[FczKGh? NGi3[nRFVVOR NUXtPWhGemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MXeyN|AyODN2OB?=
NCI/ADR-RES Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvCS5ZYOeLCk{Kwcm0> NX7yNo9CPzJiaB?= MYnEUXNQ NHvpT|Jz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? MoXvNlMxOTB|NEi=
HCT116 NWDob4h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETYZYg2KG6PLUWwJO69VQ>? NUP4O2FyOjRiaB?= MmDiSG1UVw>? MYjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M3yyR|IzQTJ2OUW4
RKO NFvkXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf2S5o2KG6PLUWwJO69VQ>? MlK4NlQhcA>? M2rodWROW09? Mn;zbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> Mn\DNlI6OjR7NUi=
CO115 M4XOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLnOUBvVS13MDFOwG0> MXSyOEBp MXLEUXNQ MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NHjQVZQzOjl{NEm1PC=>
HFS Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPrOUBvVQ>? MV2yOE81QC95MjDo Ml7SbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> NFntfWUzOjFyNkK4Ni=>
LNCaP MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW1JI5O MmGzNlQwPDhxN{KgbC=> MmnxbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MluyNlIyODZ{OEK=
A549 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnlcot4PSCwTR?= MoTPNlQwPDhxN{KgbC=> NWfCfGt2cW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? NFTRZ4kzOjFyNkK4Ni=>
697  MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rsS2lEPTEkgJm95qCKOi53wrDuUS=> NEPEeJczOTV|OEKxOi=>
697-R NXXrfHFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrMTWM2OOLCiU5ihKk5NjcEoH7NxsA> M3XoRlIyPTN6MkG2
HUT78 M4TXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV72OJp5UUN3ME2xJI5O MWSyNVE6QDV2NR?=
THJ-16T NXPTcVlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqxJI5O NWq5fYZUOjRiaB?= M3\3[4lvcGmkaYTzJINmdGxiZ4Lve5Rp MWCyNFgyODV4OB?=
HCT116 MX\GeY5kfGmxbjDBd5NigQ>? NHPycpIzOCCwTR?= NUC2UlVbQCCq MUPtc4R2dGG2ZYOgeJJidnOlcnnweEBt\X[nbIOg[o9zKGi3bnTy[YR{KG:oIHflcoV{KGmwIHXpeIhmeiCmaYLlZ5Rqd25? MYCyNFc{QTR3NB?=
B104  NHfqSGZHfW6ldHnvckBCe3OjeR?= Mo\uNkBvVQ>? NHPaVnYzPC92OD:3NkBp MYLpcoNz\WG|ZYOgeIhmKHO3cn\hZ4Uh\XiycnXzd4lwdiCxZjDDSFIxyqB? MWKyNFY5PjVyNR?=
HL-60  MnvaR5l1d3SxeHnjbZR6KEG|c3H5 NIW4S5YyNTVyMDDuUS=> NXnDRm5ROjRiaB?= MmfObY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M1;lUFIxPjJ2MU[z
HP100 NYH4bJlIS3m2b4TvfIlkcXS7IFHzd4F6 M3[5SlEuPTByIH7N Mk\QNlQhcA>? NWS4UmxncW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NYHnNYZVOjB4MkSxOlM>
HL-60  M4izdGZ2dmO2aX;uJGF{e2G7 M3G2fVExKG6P NH;ER4w1NzZxMU[gbC=> MUnpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? M3G2e|IxPjJ2MU[z
HP100 MUnGeY5kfGmxbjDBd5NigQ>? NWDhTohQOTBibl2= MUG0M|YwOTZiaB?= M4n3PYlv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= NGPKdJIzODZ{NEG2Ny=>
HL-60  MYTGeY5kfGmxbjDBd5NigQ>? M1HibFExNTVyMDDuUS=> MYG0JIg> M2\QR4Rm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NWjr[JpROjB4MkSxOlM>
HP100 MYjGeY5kfGmxbjDBd5NigQ>? MWKxNE02ODBibl2= NHK4NG01KGh? NGGwfIll\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC= M2fJPVIxPjJ2MU[z
11z NVfPe|ZEU2mwYYPlJGF{e2G7 NUjpdmxROy1zMECgcm0> NFL1bnRz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= MmXLNlA3ODVzNES=
SKOV-3 NGnHTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jsWFQwQC9zNjDuUS=> MVy0PEBp MmH4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MYSyNFQxPDV4NB?=
OVCAR-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG0M|gwOTZibl2= NU[4fFRqPDhiaB?= NG\tSnNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NIfLU44zODRyNEW2OC=>
HBL-2 NXnu[WVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S0N|IuOTBibl2= MlnpNlQhcA>? MXnJR|UxRTRwMzDuUS=> MY[yNFA3QDB6MB?=
Jeko-1 NUWwV3FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;XNk02OCCwTR?= NHi4enQzPCCq MX7JR|UxRTFzIH7N MmHWNlAxPjhyOEC=
Granta-519 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi1MVQxKG6P Mn7ENlQhcA>? NVzqUWtrUUN3ME21PE42KG6P NX\FO45kOjByNkiwPFA>
L1236 M2rC[WN6fG:2b4jpZ4l1gSCDc4PhfS=> M3zWRVEhdk1vMUCwJO69VQ>? MlvKOFghcA>? MoW5SWM2OD1yLkC3JO69VQ>? NU\4NWh{OTl{M{O0O|A>
L428 MUTDfZRwfG:6aXPpeJkhSXO|YYm= NGTaVIEyKG6PLUGwNEDPxE1? NUDBOm85PDhiaB?= MkLaSWM2OD1yLkSzJO69VQ>? MVOxPVI{OzR5MB?=
KM-H2 NVfrVHA{S3m2b4TvfIlkcXS7IFHzd4F6 M2m3SFEhdk1vMUCwJO69VQ>? NEiyNYM1QCCq NIXDNldGSzVyPUCuOVgh|ryP M4XFclE6OjN|NEew
L540Cy MmfsR5l1d3SxeHnjbZR6KEG|c3H5 M{\TcFEhdk1vMUCwJO69VQ>? NUDmd4xpPDhiaB?= NYjkbJR{TUN3ME2wMlE3KM7:TR?= MWmxPVI{OzR5MB?=
G401 MX3GeY5kfGmxbjDBd5NigQ>? M{LENVExKG6P MYOyOE81QC95MjDo NVP1UZFHTE2VTx?= MkjrbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u M{K2c|E6OjJzNUi2
STM91-01 MVrGeY5kfGmxbjDBd5NigQ>? MkDXNVAhdk1? NGjmZoEzPC92OD:3NkBp M{fXR2ROW09? MmfmbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u M3TqflE6OjJzNUi2
SJSC  NVPZTFFyTnWwY4Tpc44hSXO|YYm= Mn;RNVAhdk1? NWr6ZZZxOjRxNEivO|IhcA>? MWTEUXNQ MlzLbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NWn5[4s2OTl{MkG1PFY>
BT16  M{PwfGZ2dmO2aX;uJGF{e2G7 M4ftSFExKG6P Mln4NlQwPDhxN{KgbC=> M{G4WWROW09? NXToV|BOcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MV6xPVIzOTV6Nh?=
NCI-H1299 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG4SW5VUUN3ME20MlbDuTBwMjDu[{9udA>? M1;BUFE6OTd7OEmw
NCI-2882 NXjHdnhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwNtMxNE4xPCCwZz;tcC=> NWHVVpdrOTlzN{m4PVA>
HCC95 M3XJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37tWGlEPTB;Mj61xtExNjB3IH7nM41t MojhNVkyPzl6OUC=
NCI-H23 M4nYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO3SIhLUUN3ME2yMlnDuTBwMjDu[{9udA>? NV;tZpBZOTlzN{m4PVA>
NCI-H157 NGq1RlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf1TVNKSzVyPUGuOuKyOC5yMjDu[{9udA>? NVj2doZmOTlzN{m4PVA>
NCI-H460 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJwMdMxNE4xPyCwZz;tcC=> NVPsPVFqOTlzN{m4PVA>
NCI-H1975 NWXKWlNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKxb4tKSzVyPUGuN:KyOC5yNDDu[{9udA>? MmrUNVkyPzl6OUC=
NCI-H820 NVG1TZU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJwNNMxNE4yKG6pL33s NW\UPVk4OTlzN{m4PVA>
NCI-H1650 M17kWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTRwOdMxNE4{KG6pL33s NFXnSmEyQTF5OUi5NC=>
DTC1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrKTWM2OD1yLkWxJI5O NI[4TYMyQDV4NkK0Oi=>
KAO Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X6[WlEPTB;MD65NUBvVQ>? M3\NcVE5PTZ4MkS2
SU-CCS-1 NWfoZ3F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nsZ2lEPTB;MD64PUBvVQ>? NVm4bVd4OTh3Nk[yOFY>
SYO-1 NVW3dXRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTFUpZKSzVyPUCuOlchdk1? NVTMSZQ4OTh3Nk[yOFY>
FUJI M3fSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HVSmlEPTB;MT6zNUBvVQ>? NGH2SoUyQDV4NkK0Oi=>
SKNMC M3\FcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwMUegcm0> M{HC[|E5PTZ4MkS2
402-91 NF;JcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG0NYd5UUN3ME2xMlI3KG6P NXzFPFFOOTh3Nk[yOFY>
1765-92 M2nWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP0dIdGUUN3ME2xMlc4KG6P MUSxPFU3PjJ2Nh?=
JN-DSRCT-1 NWXvXmtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;GWGlEPTB;MT6yOUBvVQ>? M3X0b|E5PTZ4MkS2
NMS-2PC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXHTWM2OD1yLkixJI5O NG[0O5EyQDV4NkK0Oi=>
HL60 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkezTWM2OD1zLki2JI5O NHv3OYYyQDV4NkK0Oi=>
A549 NWjiRodXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnThTWM2OD1|LkK0JI5O MV:xPFU3PjJ2Nh?=
SW480 M2jOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC5OXpKSzVyPUKuOlkhdk1? MnHsNVg2PjZ{NE[=
MCF7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe1VnlKSzVyPUOuOVUhdk1? MlntNVg2PjZ{NE[=
PC-3 M3nxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGxTWM2OD1{LkWxJI5O MUKxPFU3PjJ2Nh?=
MMRU M4L0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LFXGlEPTB;Mj61O{BvVQ>? NF60b5UyQDV4NkK0Oi=>
Hs68 M3XHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRT5zMDDuUS=> NV3ETms{OTh3Nk[yOFY>
hMSC-001F MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jrUWlEPTB;PkGwJI5O M2LpWVE5PTZ4MkS2

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: HL60, Jurkat, A549, and MCF-7
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (参考用のみ)
動物試験:

[5]

+ 展開
  • 動物モデル: Male scid mice inoculated i.p. with U-937 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~1 mg/kg once or twice a week
  • 投与方法: Treated i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 540.7
化学式

C24H36N4O6S2

CAS No. 128517-07-7
保管
in solvent
別名 FR 901228, NSC 630176

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting T Cell Lymphoma Rhizen Pharmaceuticals SA March 2019 Phase 1|Phase 2
NCT03770000 Recruiting T Cell Lymphoma Rhizen Pharmaceuticals SA March 2019 Phase 1|Phase 2
NCT03703375 Recruiting Lymphoma T-Cell Celgene November 6 2018 Phase 3
NCT03593018 Recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene November 9 2018 Phase 3
NCT03703375 Recruiting Lymphoma T-Cell Celgene November 6 2018 Phase 3
NCT03593018 Recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene November 9 2018 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Romidepsin (FK228, Depsipeptide)を買う | Romidepsin (FK228, Depsipeptide) ic50 | Romidepsin (FK228, Depsipeptide)供給者 | Romidepsin (FK228, Depsipeptide)を購入する | Romidepsin (FK228, Depsipeptide)費用 | Romidepsin (FK228, Depsipeptide)生産者 | オーダーRomidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)化学構造 | Romidepsin (FK228, Depsipeptide)分子量 | Romidepsin (FK228, Depsipeptide)代理店
×

大阪市内で「G20サミット」が開催されることに伴い、大阪府内で大規模な交通規制が行われる影響で、6月26日(水)から7月1日(月)までの間、下記地域へ出荷が行えなくなります。
対象地域
大阪府(全域)、兵庫県(芦屋市、尼崎市、伊丹市、西宮市)
上記地域より西の地域につきましては納期の遅延が予想されます。
また、国際便も遅延が予想されているため国内在庫がない製品の納期が一週間程度遅れる可能性がございます。
ご不便をおかけいたしますが、宜しくお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID